[Market Feature] Hanmi Pharmaceutical Hits Record High on Expectations of Structural Growth in Obesity Drug Market

Hanmi Pharmaceutical is showing strong performance in early trading.

As of 9:05 a.m. on November 12, Hanmi Pharmaceutical was trading at 491,500 won, up 8.26% (37,500 won) from the previous day. During the session, the price soared to 492,500 won, marking a new 52-week high.

The company has been highlighted as a beneficiary of the structural growth in the obesity drug market, and a series of target price increases by securities firms has stimulated investor sentiment.

Han Seungyeon, a researcher at NH Investment & Securities, noted that Eli Lilly, listed on the New York Stock Exchange, reached an all-time high market capitalization of 900 billion dollars. He stated, "Hanmi Pharmaceutical's obesity pipeline HM15275 (LA-TRIA) is aiming to deliver superior data compared to Eli Lilly's retatrutide, which could highlight its value based on momentum," and raised his target price from 520,000 won to 560,000 won.

Within this year, the first Phase 3 results for retatrutide are expected to be announced, along with the results of MSD's MASH Phase 2b trial, which Hanmi Pharmaceutical has licensed out. There are expectations for Hanmi Pharmaceutical's mid- to long-term upside potential, given its partnerships with these companies.